肝炎治療の世界市場

◆英語タイトル:Hepatitis Therapeutics Market (Disease Type - Hepatitis A, Hepatitis B, Hepatitis C; Drug Class - Nucleotide Analog Reverse Transcriptase Inhibitor, NS5A Inhibitor, Multi-class Combination, Nucleotide Analog NS5B Polymerase Inhibitor, Interferon and Ribavirin; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
◆商品コード:TPM-C03043
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2019年1月
◆ページ数:183
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Global Site LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Researchが調査・発行した当レポートは、肝炎治療の世界市場について調べ、肝炎治療の世界規模、市場動向、市場環境、タイプ別(A型肝炎、B型肝炎、C型肝炎)分析、薬剤クラス別(ヌクレオチドアナログ逆転写酵素阻害剤、NS5A阻害剤、マルチクラス併用剤、ヌクレオチドアナログNS5Bポリメラーゼ阻害剤、インターフェロン・リバビリン)分析、流通経路別(院内薬局、小売薬局、オンライン薬局)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめました。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・肝炎治療の世界市場動向
・肝炎治療の世界市場環境
・肝炎治療の世界市場規模
・肝炎治療の世界市場規模:タイプ別(A型肝炎、B型肝炎、C型肝炎)
・肝炎治療の世界市場規模:薬剤クラス別(ヌクレオチドアナログ逆転写酵素阻害剤、NS5A阻害剤、マルチクラス併用剤、ヌクレオチドアナログNS5Bポリメラーゼ阻害剤、インターフェロン・リバビリン)
・肝炎治療の世界市場規模:流通経路別(院内薬局、小売薬局、オンライン薬局)
・肝炎治療の世界市場:地域別市場規模・分析
・肝炎治療の北米市場規模・予測
・肝炎治療のアメリカ市場規模・予測
・肝炎治療の中南米市場規模・予測
・肝炎治療のヨーロッパ市場規模・予測
・肝炎治療のアジア市場規模・予測
・肝炎治療の日本市場規模・予測
・肝炎治療の中国市場規模・予測
・肝炎治療のインド市場規模・予測
・肝炎治療の中東市場規模・予測
・肝炎治療のアフリカ市場規模・予測
・競争状況・関連企業情報
【レポートの概要】

Global Hepatitis Therapeutics Market: Overview

This report analyzes the current and future scenario of the global hepatitis therapeutics market. Increase in the prevalence of viral hepatitis, promising hepatitis drug pipeline, and favorable government support are the major drivers of the global market.

The global hepatitis therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on disease type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises company profiles with product portfolio to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by region, and market share analysis, by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hepatitis therapeutics market.

Global Hepatitis Therapeutics Market: Key Segments

The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region. In terms of disease type, the global market has been segmented into hepatitis A, hepatitis B, hepatitis C, and others. Based on drug class, the global hepatitis therapeutics market has been categorized into nucleotide analog reverse transcriptase inhibitor, NS5A inhibitor, multi- class combination, nucleotide analog NS5B polymerase inhibitor, interferon & ribavirin, and others. Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and others. The market value and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Hepatitis Therapeutics Market: Regional Outlook

The global hepatitis therapeutics market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). The Market Value and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global hepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, recent developments, and SWOT analysis. Major companies profiled in the report are Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., F. Hoffmann-La Roche, Ltd., LAURUS Labs, AbbVie Inc., Hetero Healthcare Limited, Zydus Cadila, Cipla, Inc., and NATCO Pharma Limited.

The global hepatitis therapeutics market has been segmented as below:

Global Hepatitis Therapeutics Market, by Disease
Hepatitis A
Hepatitis B
Hepatitis C
Others
Global Hepatitis Therapeutics Market, by Drug Class
Nucleotide Analog Reverse Transcriptase Inhibitor
NS5A Inhibitor
Multi Class Combination
Nucleotide Analog NS5B Polymerase Inhibitor
Interferon & Ribavirin
Others
Global Hepatitis Therapeutics Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatitis Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hepatitis Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Pipeline Analysis
5.2.New Product Launch, Approvals & Patent Expiry
5.3.Regulatory Scenario

6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Disease Type, 2016–2026
6.2.1. Hepatitis A
6.2.2. Hepatitis B
6.2.3. Hepatitis C
6.2.4. Others
6.3. Market Attractiveness, by Disease Type

7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class
7.1. Introduction & Definition
7.2. Market Value Forecast, by Drug Class, 2016–2026
7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.2.2. NS5A Inhibitor
7.2.3. Multi Class Combination
7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.2.5. Interferon & Ribavirin
7.2.6. Others
7.3. Market Attractiveness, by Drug Class

8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Market Value Forecast, by Distribution Channel, 2016–2026
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel

9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region
9.1. Market Value Forecast, by Region
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Market Attractiveness, by Country/Region

10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1.Introduction
10.2.Market Value Forecast, by Disease Type, 2016–2026
10.2.1. Hepatitis A
10.2.2. Hepatitis B
10.2.3. Hepatitis C
10.2.4. Others
10.3.Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.3.2. NS5A Inhibitor
10.3.3. Multi Class Combination
10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.3.5. Interferon & Ribavirin
10.3.6. Others
10.4.Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5.Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6.Market Attractiveness, Analysis
10.6.1.By Disease Type
10.6.2. B Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1.Introduction
11.2.Market Value Forecast, by Disease, 2016–2026
11.2.1. Hepatitis A
11.2.2. Hepatitis B
11.2.3. Hepatitis C
11.2.4. Others
11.3.Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.3.2. NS5A Inhibitor
11.3.3. Multi-class Combination
11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.3.5. Interferon & Ribavirin
11.3.6. Others
11.4.Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5.Market Value Forecast, by Country, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness, Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country

12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1.Introduction
12.2.Market Value Forecast, by Disease Type, 2016–2026
12.2.1. Hepatitis A
12.2.2. Hepatitis B
12.2.3. Hepatitis C
12.2.4. Others
12.3.Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.3.2. NS5A Inhibitor
12.3.3. Multi-class Combination
12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.3.5. Interferon & Ribavirin
12.3.6. Others
12.4.Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5.Market Value Forecast, by Country, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness, Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country

13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1.Introduction
13.2.Market Value Forecast, by Disease Type, 2016–2026
13.2.1. Hepatitis A
13.2.2. Hepatitis B
13.2.3. Hepatitis C
13.2.4. Others
13.3.Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.3.2. NS5A Inhibitor
13.3.3. Multi-class Combination
13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.3.5. Interferon & Ribavirin
13.3.6. Others
13.4.Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5.Market Value Forecast, by Country, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness, Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country

14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1.Introduction
14.2.Market Value Forecast, by Disease Type, 2016–2026
14.2.1. Hepatitis A
14.2.2. Hepatitis B
14.2.3. Hepatitis C
14.2.4. Others
14.3.Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.3.2. NS5A Inhibitor
14.3.3. Multi-class Combination
14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.3.5. Interferon & Ribavirin
14.3.6. Others
14.4.Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5.Market Value Forecast, by Country, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.5. Rest of Middle East & Africa
14.6.Market Attractiveness, Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country

15. Competition Landscape
15.1.Market Share Analysis, by Company (2017)
15.2. Company Profiles
15.2.1. Gilead Sciences, Inc.
15.2.2. F. Hoffmann-La Roche, Ltd.
15.2.3. Bristol Myers Squibb
15.2.4. Merck & Co., Inc.
15.2.5. AbbVie Inc.
15.2.6. NATCO Pharma Limited
15.2.7. Zydus Cadila
15.2.8. Hetero Healthcare Limited
15.2.9. LAURUS Labs
15.2.10. Cipla, Inc.

List of Tables

Table 01: Pipeline Analysis
Table 02: Pipeline Analysis
Table 03: Pipeline Analysis
Table 04: New Product Launch, Approvals & Patent Expiry
Table 05: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026 2016–2026
Table 06: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 07: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 10: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 11: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 12: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 13: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 14: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 15: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 16: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 17: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 18: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 19: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 20: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 21: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 22: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 23: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 24: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 25: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 26: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 27: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 28: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026


List of Figures

Figure 01: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type (2017)
Figure 03: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class (2017)
Figure 04: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel (2017)
Figure 05: Global Hepatitis Therapeutics Market Value Share (%), by Region (2017)
Figure 06: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 07: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis A, 2016–2026
Figure 08: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis B, 2016–2026
Figure 09: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis C, 2016–2026
Figure 10: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 11: Global Hepatitis Therapeutics Market Attractiveness,, by Disease Type, 2018–2026
Figure 12: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 13: Global Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 14: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog Reverse Transcriptase Inhibitor, 2016–2026
Figure 15: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NS5A Inhibitor, 2016–2026
Figure 16: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multi-class Combination, 2016–2026
Figure 17: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog NS5B Polymerase Inhibitor, 2016–2026
Figure 18: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interferon & Ribavirin, 2016–2026
Figure 19: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 20: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 21: Global Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 22: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 23: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 24: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 25: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2018 and 2026
Figure 26: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 27: North America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 28: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 29: North America Hepatitis Therapeutics Market AttractivenessAnalysis, by Country, 2018–2026
Figure 30: North America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 31: North America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 32: North America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 33: North America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 34: North America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 35: North America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Europe Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 37: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 38: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 39: Europe Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 40: Europe Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 41: Europe Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 42: Europe Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 43: Europe Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 44: Europe Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 46: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 47: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 48: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 49: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 50: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 51: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 52: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 53: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 54: Latin America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 55: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 56: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 57: Latin America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 58: Latin America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 59: Latin America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 60: Latin America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 61: Latin America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 62: Latin America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 64: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 65: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 66: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 67: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 68: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 69: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 70: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 71: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 72: Global Hepatitis Therapeutics Market Share, by Company, 2017


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肝炎治療の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆